Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Post by wordlesson May 21, 2013 4:48pm

202 Views

Post# 21422903

PINETREE CAPITAL LTD. ACQUIRES SECURITIES OF WOLFP

PINETREE CAPITAL LTD. ACQUIRES SECURITIES OF
WOLFPACK GOLD CORP.

To view the release online, please click here

TORONTO, Canada (May 21, 2013) Pinetree Capital Ltd. (TSX: PNP), announces that on May 21, 2013, as a result of a reverse take-over by Wolfpack Gold of Tigris Uranium Corp., it acquired ownership of 4,266,666 common shares (“Common Shares”) of Wolfpack Gold Corp. (“Wolfpack”) representing approximately 8.6% of the total issued and outstanding common shares of Wolfpack as of May 21, 2013. As a result of this transaction, Pinetree and its joint actors collectively held, as at May 21, 2013, an aggregate of 6,041,666 common shares of Wolfpack, including the Common Shares, representing approximately 12.2% of all issued and outstanding common shares as at May 21, 2013.

These transactions were made for investment purposes and Pinetree or its joint actors could increase or decrease their investment in Wolfpack depending on market conditions or any other relevant factor.

About Pinetree
Pinetree Capital Ltd. ("Pinetree") was incorporated under the laws of the Province of Ontario and its shares are publicly-traded on the Toronto Stock Exchange (“TSX”) under the symbol “PNP”. Pinetree is a diversified investment and venture capital firm focused on the small cap market. Pinetree’s investments are primarily in the resources sector: Precious Metals, Base Metals, Oil and Gas, Potash, Lithium and Rare Earths, Uranium and Coal. Pinetree’s investment approach is to develop a macro view of a sector, build a position consistent with the view by identifying micro-cap opportunities within that sector, and devise an exit strategy designed to maximize our relative return in light of changing fundamentals and opportunities. Pinetree is recognized as a value-added partner in the resource industry.

For more details about Pinetree and its investments, please visit our website at www.pinetreecapital.com

Sheldon Inwentash, CPA., CA. Chairman & CEO Pinetree Capital Ltd. Gerry Feldman, CPA., CA. CFO & Vice President, Corporate Development Pinetree Capital Ltd. Phone: 416-643-3884 Email: feldman@pinetreecapital.com	Investor Relations: Richard Patricio, LL.B. Vice President, Legal and Corporate Affairs Pinetree Capital Ltd. 130 King Street West, Suite 2500 Toronto, Ontario, Canada, M5X 1A9 Phone: 416-941-9600 Email: ir@pinetreecapital.com Web Site: www.pinetreecapital.com